CSPC
Biomedical R&D company
CSPC, founded in June, 1992 and headquartered in Shijiazhuang, is a biopharmaceutical developer. The founder is Cai Dongchen. Listed on the HKEX on June 21, 1994, the company's major shareholders are Massive Top. Limited. Rivals that have direct and indirect competition with CSPC include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
East China medicine "liraglutide" goes to sea
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Real Estate, Consumer Discretionary, IndustrialsTech for Global, Globalization Footprints of the Established and the New
Research
Real Estate, Consumer Discretionary, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Mojia biology announced the completion of round B financing
First class recall of Draeger, a ventilator giant
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%